左乳腺癌保乳术后全乳和锁骨上下及内乳淋巴结区三种放疗方式的剂量学研究

冯旭东; 张勇; 岳麒; 肖斌; 张燕华; 李荣清

doi:10.3969/j.issn.1000-8179.2020.08.405

左乳腺癌保乳术后全乳和锁骨上下及内乳淋巴结区三种放疗方式的剂量学研究

doi: 10.3969/j.issn.1000-8179.2020.08.405

冯旭东^①,,
张勇^①,
岳麒^①,
肖斌^②,
张燕华^①,
李荣清^①, ,

①.
昆明医科大学第一附属医院肿瘤放疗科(昆明市 650000)
②.
云南大学材料学院云南省微纳米材料与技术重点实验室

详细信息

作者简介:
冯旭东, 专业方向为头颈部及胸部肿瘤的放疗及综合治疗。E-mail:fxd23@sina.com

通讯作者:
李荣清, lrqmxl@162.com

计量
- 文章访问数: 187
- HTML全文浏览量: 90
- PDF下载量: 7
- 被引次数: 0
出版历程
- 收稿日期: 2020-03-20
- 刊出日期: 2020-12-26

Dosimetric study of three different irradiation methods of treating left breast cancer with total breast and clavicle and internal breast lymph node area after breast conservative surgery

Xudong Feng^{①
,},
Yong Zhang^①,
Qi Yue^①,
Bin Xiao^②,
Yanhua Zhang^①,
Rongqing Li^{①
, ,}

①.
Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical College, Yunnan 650032, China
②.
School of Materials Science and Engineering, Yunnan Key Laboratory for Micro/Nano Materials & Technology, Yunnan University, Kunming 650091, China

More Information

Corresponding author: Rongqing Li; E-mail:lrqmxl@162.com

摘要

摘要: 目的对左乳腺癌保乳术后全乳及锁骨上下、内乳淋巴结引流区三种放疗方式在靶区及危及器官（organs at risk，OARs）的剂量学进行研究。方法选取2018年1月至2019年10月20例于昆明医科大学第一附属医院行左乳腺癌保乳术后放疗患者的定位CT资料，设计固定野滑窗调强放疗（dynamic multi-leaf collimator，dMLC）、容积弧形调强放疗（volumetric intensity modulated arctherapy，VMAT）和螺旋断层放疗（tomotherapy，HT）三种计划，并对剂量指标进行统计学分析。结果 HT在术后瘤床（plan targetvolume of tumor bed，PTV_tb）的平均剂量（mean dose，D_mean）、D₁、适形度（homogeneity index，HI）和全乳及淋巴引流区的计划靶区（plan target volume，PTV）的D_mean、均匀性（conformity index，CI）均优于dMLC和VMAT，并且降低心脏和患侧肺的D_mean、V₅、V₁₀、V₃₀。HT在冠状动脉左前降支和右冠状动脉的D_mean以及D₁比较中剂量最低，但相比VMAT及dMLC，HT增加健侧乳腺的D₁和D_mean。结论对左乳腺癌保乳术后患者，HT对降低心脏毒性和保护患侧肺最有优势，但对健侧肺低剂量控制不如VMAT和dMLC，dMLC对健侧肺及健侧乳腺低剂量控制最佳，但对心脏及患侧肺的高剂量控制最差。在临床中需根据实际情况选择合适的计划方式。
- 调强放疗 /
- 保乳术 /
- 乳腺癌 /
- 内乳淋巴结 /
- 剂量学
Abstract: Objective To evaluate the differences in dosimetry distribution among three different radiotherapy methods used for the treatment of left breast cancer affecting the total breast, clavicle, and internal breast lymphatic drainage area after breast-conserving surgery. The target coverage and organs at risk (OARs) in each method were compared. Methods Twenty breast cancer patients who were treated at First Affiliated Hospital of Kunming Medical College, from January 2018 to October 2019 were selected. All patients underwent left-side breast conserving postoperative radiotherapy. Dynamic multi-leaf collimator (dMLC), volumetric modulated arc therapy (VMAT), and helical tomotherapy (HT) plans were designed for each patient. We compared and analyzed the parameters of planning target volume of the tumor bed (PTV_tb), planning target volume (PTV), and OARs according to these plans using a paired t-test. Results The mean dose (D_mean), D₁, homogeneity index (HI) of PTV_tb, D_mean, and conformity index (CI) of the PTV of the HT plan were better than those of the DMLC and VMAT plans. The D_mean, V₅, V₁₀, and V₃₀ of the heart and lungs were significantly decreased in the HT plan. The HT plan had the lowest D_mean and D₁ values for the left anterior descending coronary artery and right coronary artery. However, compared with the VMAT and DMLC plans, the HT plan had increased values for D₁ and D_mean of the right breast. Conclusion For patients with left breast cancer who have undergone breast conserving surgery, HT can reduce the dose to the ipsilateral lung and heart. However, the low-dose area of the contralateral lung was larger with the HT plan than with the VMAT and dMLC plans. With the dMLC plan, the dose to the contralateral lung was the lowest, but the doses to the ipsilateral lung and heart were higher than those with the VMAT and HT plans. An appropriate treatment plan should be chosen according to the condition of the patient.
- intensity modulated radiotherapy /
- breast conserving surgery /
- breast cancer /
- internal breast lymph nodes /
- dosimetry

HTML全文

图 1 三种治疗方式的计划设野图

A：dMLC；B：VMAT；C：HT

下载: 全尺寸图片幻灯片

图 2 三种治疗方式的剂量分布图

A：dMLC；B：VMAT；C：HT

下载: 全尺寸图片幻灯片

表 1 左乳腺癌患者三种治疗方式的靶区剂量参数比较

表 2 左乳腺癌患者三种治疗方式的肺部剂量参数比较

表 3 左乳腺癌患者三种治疗方式的心脏及冠状动脉剂量参数比较

表 4 左乳腺癌患者三种治疗方式的健侧乳腺、脊髓、气管和甲状腺的剂量参数比较

参考文献(15)

[1]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0234398683/
[2]	Graham MV, Purdy JA, Emami B, et al. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer[J]. Int J Radiat Oncol Biol Phys, 1995, 33(5):993-1000. http://cn.bing.com/academic/profile?id=1df36d90741d919a43a854b9cdd6bd98&encoded=0&v=paper_preview&mkt=zh-cn
[3]	Schallenkamp JM, Miller RC, Brinkmann DH, et al. Incidence of radiation pneumonitis after thoracic irradiation:dose-volume correlates[J]. Int J Radiat Oncol Biol Phys, 2007, 67(2):410-416. http://cn.bing.com/academic/profile?id=647e562172eaafa9d6b5692f6072f605&encoded=0&v=paper_preview&mkt=zh-cn
[4]	Haciislamoglu E, Colak F, Canyilmaz E, et al. Dosimetric comparison of left-sided whole-breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and volumetric arc therapy[J]. Phys Med, 2015, 31(4):360-367. http://cn.bing.com/academic/profile?id=3ba31759c28e940123f6e4a79499754e&encoded=0&v=paper_preview&mkt=zh-cn
[5]	Mackie TR, Holmes T, Swerdloff S, et al. Tomotherapy:a new concept for the delivery of dynamic conformal radiotherapy[J]. Med Phys, 1993, 20(6):1709-1719. http://d.old.wanfangdata.com.cn/Periodical/zhfsyxyfhzz98201705006
[6]	Langen KM, Papanikolaou N, Balog J, et al. QA for helical tomotherapy:report of the AAPM task group 148[J]. Med Phys, 2010, 37(9):4817-4853. http://cn.bing.com/academic/profile?id=1753418071d06ef9251e13fae9cd3fba&encoded=0&v=paper_preview&mkt=zh-cn
[7]	Lee HH, Chen CH, Luo KH, et al. Five-year survival outcomes of intensity-modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) using forward IMRT or Tomotherapy for breast cancer[J]. Sci Rep, 2020, 10(1):4342. http://cn.bing.com/academic/profile?id=613772acc1af6084abea3fb0823868a4&encoded=0&v=paper_preview&mkt=zh-cn
[8]	Stewart FA. Mechanisms and dose-response relationships for radiation-induced cardiovascular disease[J]. Ann ICRP, 2012, 41(3-4):72-79. http://cn.bing.com/academic/profile?id=256c1afd1fd26abf86a786dfb955fbb5&encoded=0&v=paper_preview&mkt=zh-cn
[9]	Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer[J]. N Engl J Med, 2013, 368(11):987-998. http://cn.bing.com/academic/profile?id=97cc087ec58fb564521f4f4e1ca78a76&encoded=0&v=paper_preview&mkt=zh-cn
[10]	陈偲晔, 王淑莲.乳腺癌放射性心脏损伤(RIHD)的评估和预防研究进展[J].中华放射肿瘤学杂志, 2017, 26(4):474-480. http://d.old.wanfangdata.com.cn/Periodical/zhfszl201704024
[11]	Gyenes G, Gagliardi G, Lax I, et al. Evaluation of irradiated heart volumes in stage I breast cancer patients treated with postoperative adjuvant radiotherapy[J]. J Clin Oncol, 1997, 15(4):1348-1353. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=846097ca11798912831c53295faa0ac7
[12]	杨波, 刘志凯, 侯晓荣, 等.乳腺癌保乳术后螺旋断层治疗技术的剂量学研究[J].中华放射肿瘤学杂志, 2013, 22(5):411-414. http://d.old.wanfangdata.com.cn/Periodical/zhfszl201305021
[13]	陈慧茹, 王石, 吴朝霞, 等.乳腺癌保乳术后全乳及锁骨上下区三种调强剂量学分析[J].中华放射肿瘤学杂志, 2017, 26(7):774-777. http://d.old.wanfangdata.com.cn/Periodical/zhfszl201707011
[14]	Di Betta E, Fariwlli L, BergantinA, et al. Evaluation of the peripheral dose in stereotactic radiotherapy and radiosurgery treatments[J]. Med Phys, 2010, 37(7):3587-3594. http://cn.bing.com/academic/profile?id=a7b09ea6fe529c5d57e3fade5a65bb7c&encoded=0&v=paper_preview&mkt=zh-cn
[15]	Unnithan J, Macklis RM. Contralateral breast cancer risk[J]. Radiother Oncol, 2001, 60(3):239-246. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0228920633/